Literature DB >> 10786895

Proteomics in molecular medicine: applications in central nervous systems disorders.

C Rohlff1.   

Abstract

Bodily fluids such as cerebrospinal fluid (CSF) and serum can be analysed at the time of presentation and throughout the course of the disease. Changes in the protein composition of CSF may be indicative of altered CNS protein expression pattern with a causative or diagnostic disease link. These findings can be strengthened through subsequent proteomic analysis of specific brain areas implicated in the pathology. New isolation strategies of clinically relevant cellular material such as laser capture microdissection, protein enrichment procedures and proteomic approaches to neuropeptide and neurotransmitter analysis give us the opportunity to map out complex cellular interaction at an unprecedented level of detail. In neurological disorders multiple underlying pathogenic mechanisms as well as an acute and a chronic CNS disease components may require a selective repertoire of molecular targets and biomarkers rather than an individual protein to better define a complex disease. The resulting proteome database bypasses many ambiguities of experimental models and may facilitate pre- and clinical development of more specific disease markers and new selective fast acting therapeutics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10786895     DOI: 10.1002/(SICI)1522-2683(20000401)21:6<1227::AID-ELPS1227>3.0.CO;2-L

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  22 in total

1.  Proteomic profiling and neurodegeneration in Alzheimer's disease.

Authors:  T Tsuji; A Shiozaki; R Kohno; K Yoshizato; S Shimohama
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

2.  Multiple reaction monitoring assay based on conventional liquid chromatography and electrospray ionization for simultaneous monitoring of multiple cerebrospinal fluid biomarker candidates for Alzheimer's disease.

Authors:  Yong Seok Choi; Kelvin H Lee
Journal:  Arch Pharm Res       Date:  2015-09-24       Impact factor: 4.946

3.  Developmental changes in the neuronal protein composition: a study by high resolution 2D-gel electrophoresis.

Authors:  Munmun Chatterjee; Diptendu Chatterjee
Journal:  Mol Cell Biochem       Date:  2005-04       Impact factor: 3.396

Review 4.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

Review 5.  Two-dimensional protein electrophoresis: from molecular pathway discovery to biomarker discovery in neurological disorders.

Authors:  Leila H Choe; Brenda G Werner; Kelvin H Lee
Journal:  NeuroRx       Date:  2006-07

6.  Optimized proteomic analysis of a mouse model of cerebellar dysfunction using amine-specific isobaric tags.

Authors:  Jun Hu; Jin Qian; Oleg Borisov; Sanqiang Pan; Yan Li; Tong Liu; Longwen Deng; Kenneth Wannemacher; Michael Kurnellas; Christa Patterson; Stella Elkabes; Hong Li
Journal:  Proteomics       Date:  2006-08       Impact factor: 3.984

7.  Proteomic analysis of neuronal hypoxia in vitro.

Authors:  K Jin; X O Mao; D A Greenberg
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

8.  Cobalamin (vitamin B12)-deficiency-induced changes in the proteome of rat cerebrospinal fluid.

Authors:  Elisabetta Gianazza; Daniela Veber; Ivano Eberini; Francesca R Buccellato; Elena Mutti; Luigi Sironi; Giuseppe Scalabrino
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

9.  Proteomic analysis of rat brains following exposure to electroconvulsive therapy.

Authors:  Cheol Soon Lee; Kee Ryeon Kang; Ji-Young Lee; Chul Soo Park; Kyu Hee Hahn; Jin Wook Sohn; Bong Jo Kim
Journal:  J Korean Med Sci       Date:  2009-02-28       Impact factor: 2.153

10.  Genomic and Proteomic Biomarker Discovery in Neurological Disease.

Authors:  Rilee H Robeson; Andrew M Siegel; Travis Dunckley
Journal:  Biomark Insights       Date:  2008-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.